74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
G Guerbet
G
Closed
26.75 0.38
Overview
Share price change
24h
Min
26.75
Max
27
Income | 11M |
|---|---|
Sales | 425M |
P/E Sector Avg | 10.671 73.394 |
Dividend yield | 1.87 |
Profit margin | 2.584 |
Employees | 2,920 |
EBITDA | 60M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -28.1 downside |
Dividend yield Sector Avg | 1.87% 3.09% |
|---|---|
Next Earnings | 26 Mar 2025 |
Market Cap | 331M |
|---|---|
Previous open | 26.37 |
Previous close | 26.75 |
Technical Score
By Trading Central
Confidence
Very Strong Bullish Evidence
Guerbet Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Guerbet Forecast
Price Target
By TipRanks
-28.1% downside
12 Months Forecast
Average 19.341 EUR -28.1%
High 19.345 EUR
Low 19.345 EUR
Based on 1 Wall Street analysts offering 12 month price targets forGuerbet - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Guerbet
Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was incorporated in 1926 and is headquartered in Villepinte, France.
